tiprankstipranks
ASKA Pharmaceutical Expands Southeast Asian Presence with Hataphar Acquisition
Company Announcements

ASKA Pharmaceutical Expands Southeast Asian Presence with Hataphar Acquisition

Story Highlights

Maximize Your Portfolio with Data Driven Insights:

  • Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
  • Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) has issued an announcement.

ASKA Pharmaceutical Co., Ltd. announced its decision to acquire additional shares of Ha Tay Pharmaceutical Joint Stock Company, a Vietnamese pharmaceutical firm, making it a consolidated subsidiary. This move aligns with ASKA’s Medium-Term Management Plan 2025 to enhance its presence in the rapidly growing Southeast Asian market and further its corporate value through strategic overseas expansion.

More about ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Pharmaceutical Holdings Co., Ltd. operates in the pharmaceutical industry with a focus on the production and sale of ethical pharmaceuticals, over-the-counter drugs, and health foods. The company is primarily engaged in the healthcare sector with a strong emphasis on obstetrics and gynecology, aiming to expand its business in Southeast Asia.

YTD Price Performance: -6.29%

Average Trading Volume: 58,094

Technical Sentiment Consensus Rating: Hold

Current Market Cap: Yen55.89B

For an in-depth examination of 4886 stock, go to TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App